Vor Biopharma Rg

Clinically‑stage genome‑edited cell therapy company focused on acute myeloid leukemia, advancing multiple allogeneic HSC and CAR‑T candidates, including trem‑cel + VCAR33, with strategic licenses from NIH, Columbia and Editas. Based in Cambridge, MA.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 154
HQ: Cambridge

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
VOR	Vor Biopharma Rg Cap: 0.3B	EQUITY	NMS	USD	US9290331084	Active	📈